KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBIT: 2014-2025

Historic EBIT for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $29.7 million.

  • Aurinia Pharmaceuticals' EBIT rose 153.19% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 314.14%. This contributed to the annual value of -$4.7 million for FY2024, which is 94.89% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' EBIT is $29.7 million, which was up 48.11% from $20.1 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBIT peaked at $29.7 million during Q3 2025, and registered a low of -$50.5 million during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' EBIT averaged around -$2.2 million, with its median value being -$1.7 million (2024).
  • In the last 5 years, Aurinia Pharmaceuticals' EBIT tumbled by 306.17% in 2021 and then surged by 1,427.36% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' EBIT stood at -$32.7 million in 2021, then grew by 14.08% to -$28.1 million in 2022, then decreased by 5.60% to -$29.7 million in 2023, then soared by 94.38% to -$1.7 million in 2024, then soared by 153.19% to $29.7 million in 2025.
  • Its EBIT was $29.7 million in Q3 2025, compared to $20.1 million in Q2 2025 and $21.8 million in Q1 2025.